We're coming soon

At Quercus, we are pioneering genetic therapies for fatal diseases of the central nervous system. Our lead program treats a novel target in the pathophysiology of ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s Disease). Thanks to innovative discoveries from our founders at leading Boston area universities and hospitals, we have developed a new way to deliver this drug to the brain using liquid nanoparticle technology paired with cell surface homing ligands that can help penetrate the blood brain barrier.